Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 17, 1997 - Issue 6
Submit an article Journal homepage
7
Views
2
CrossRef citations to date
0
Altmetric
Research Article

The effects of somatostatin in the polycystic ovary syndrome

BARBARA ROSINA, DONATELLA DE FUSCO L. FALSETTI Department of Gynaecological Endocrinology, University of Brescia, Italy
Pages 560-564 | Published online: 02 Jul 2009

  • AcËbay O. and Gundogd u S. (1996) Can metformin reduce insulin resistanc e in polycystic ovary syndrome? Fertility and Sterilit y, 65, 946-949.
  • Adashi E. Y., Hsueh A. J. W. and Yen S. S. C. (1981) Insulin enhancement of luteinizing hormone and follicle -stimulating hormone release by cultured pituitary cells. Endocrinology, 108, 1441-1449.
  • Adashi E. Y., Resnick C. E., D– Ercole J. A., Svoboda J. E. and Van Wyk J. J. (1985) Insulin- like growth factors as intraovarian regulato rs of granulo sa cell growth and function. Endocrin e Reviews, 6, 400-420.
  • Adashi E. Y., Resnick C. E., Hernandez E. R., Svoboda M. E. and Van Wyk J. J. (1988) In vivo regulation of granulosa cell somatomedin-C/insulin- like growth factor I receptors. Endocrino logy, 122, 1383-1389.
  • Anttila L., Koskinen P., Jaatine n T., Erkkola R., Irjala K. and Ruutiaine n K. (1993) Insulin hypersec retion together with high luteinizing hormone concentration augments androge n secretion in oral glucose tolerance test in women with polycystic ovarian disease. Human Reproduction , 8, 1179-1183.
  • Barbieri R. L. Smith S. and Ryan K. J. (1988) The role of hyperinsulinemia in the pathogenesis of ovarian hyper-androge nism. Fertility and Sterility, 50, 197-212.
  • Bauer W., Briner V., Doepfner W., Haller R., Huguenin R., Marbach P. and Petcher T. J. (1982) SMS 201-995 : a very potent and selectiv e octapeptide analogu e of somatostatin with prolong ed action. Life Sciences, 31, 1133-1140.
  • Bloom S. R. and Polak J. M. (1987) Somatostatin. British Medical Journal, 295, 288-290.
  • Blumenfeld Z. and Lunenfeld B. (1989) The potentiating effect of growth hormone on follicle stimulation with human menopausal gonadot ropin in a panhypo pituitary patient. Fertility and Sterility, 52, 328-331.
  • Ciaraldi T. P., El-Roeiy A., Madar Z., Reichar t D., Olefsky J. M. and Yen S. S. C. (1992) Cellular mechanism of insulin resistanc e in polycystic ovaria n syndro me. Journal of Clinical Endocrino logy and Metabolism, 75, 577-582.
  • Clausen J., Hansen T., Bjobaek C., Echwalds S., Urham-mer S., Rasmussen S., Andersen C., Hansen L., Almind K., Winther K., Haraldsdottir J. and Borch-Joh nsen K. (1995) Insulin resistanc e: interactions between obesity and a common varian t of insulin receptor substrate -1. Lancet, 346, 397-402.
  • Conway G. S. and Jacobs H. S. (1993) Clinical implication sofhyperin sulinemiainwomen.Clinical Endocrino logy, 39, 623-632.
  • Dale P. O., Tanbo T., Vaaler S. and Abyholm T. (1992) Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndro me: evidenc e of two distinct populat ions. Fertility and Sterility, 58, 487-491.
  • Doldi N., Bassan M., Bonzi V. and Ferrari A. (1996) Effects ofgrowthhormone andgrowthhormone-releasing hormone on steroid synthesis in culture d humanluteinizinggranulo sacells.Gynecolog ical Endocrino logy, 10, 101-108.
  • Dunaif A., Mandeli J., Fluhr H. and Dobrjansky A. (1988) The impact of obesity and chronic hyperin sulinemia on gonadotropin release and gonadal steroid secretio n in the polycystic ovary syndro me. Journa l of Clinical Endocrino logy and Metabolism, 66, 131-139.
  • Dunaif A., Segal K. R., Shelley D. R., Green G., Dobrjan-sky A. and Lichola i T. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrom e. Diabetes, 41, 1257-1266.
  • Dunaif A., Scott D., Finegoo d D., Quintana B. and Whitcomb R. (1996) The insulin- sensitizing agent troglita -zone improves metabolic and reprodu ctive abnormalities in the polycystic ovary syndro me. Journal of Clinical Endocrino logy and Metabolism, 81, 3299-3305.
  • Ferriman D. and Gallway J. D. (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrino logy and Metabolism, 21, 1440-1448.
  • Franks S. (1995) Polycystic ovary syndro me. New England Journal of Medicine, 333, 853-861.
  • Fulghesu A. M., Lanzone A., Andrean i C. L., Pierro E., Caruso A. and Mancuso S. (1995) Effectiveness of a somatostatin analogue in lowering luteiniz ing hormone and insulin- stimulated secretion in hyperin sulinemic women with polycystic ovary disease. Fertility and Sterility , 64, 703-708.
  • Homburg R., Eshel A., Abdalla H. I. and Jacobs H. S. (1988) Growth hormone facilitates ovulation induction by gonadotropins. Clinical Endocrino logy, 29, 113-117.
  • Homburg R., Pariente C., Lunenfeld B. and Jacobs H. S. (1992) The role of insulin- like growth factor-1 (IGF-1) and IGF binding protein- 1 (IGFBP-1) in the pathoge ne-sis of polycystic ovary syndro me. Human Reproduc tion, 7, 1379-1383.
  • Hull M. G. R. (1987) Epidemiology of infertility and polycystic ovarian disease : endocrinologic al and demographic studies. Gynecolog ical Endocrino logy, 1, 235-245.
  • Jahanfa r S., Eden J. A., Warren P., Seppala M. and Nguyen T. V. (1995) A twin study of polycystic ovary syndro me. Fertility and Sterility, 63, 478-486.
  • Jia X. C., Kamljn J., and Hsueh A. J. W. (1986) Growth hormone enhance s follicle -stimulating hormone-ind uced differentiationofculturedratgranulo sacells. Endocrino logy, 118, 1401-1409.
  • Kutz K., Nueesch E. and Rosenthaler J. (1986) Pharmacokinetics of SMS 201-99 5 in healthy subjects. Scandinavian Journa l of Gastroente rology, 119, supplement, 65-72.
  • Lanzone A., Fulghesu A. M., Andrean i C. L., Apa R., Fortini A., Caruso A. and Mancuso S. (1990) Insulin secretion in polycystic ovaria n disease: effect of ovaria n suppression by Gn-RH agonist. Human Reproduct ion, 5, 143-149.
  • Longneck er S. M. (1988) Somatostati n and octreotide: literatu re review and description of therapeutic activity in pancreatic neoplasia. Drug Intellige nce and Clinical Pharm acy, 22, 99-106.
  • Martin J. L. and Baxter R. C. (1994) Regulatio n and action s of the insulin-like growth factor binding proteins. Current Opinion in Endocrino logy and Diabete s, 16-21.
  • Morris D. V. and Falcone T. (1996) The relation ship betweeninsulinsensitivityandinsulin-likegrowth factor-binding protein- 1. Gynecolog ical Endocrino logy, 10, 407-412.
  • Morris R. S., Carmina E., Vijod M. A., Stanczy k F. Z. and Lobo R. A. (1995) Alteration s in the sensitivity of serum insulin-like growth factor 1 and insulin- like growth factor bindin g protein-3 to octreoti de in polycystic ovary syndrom e. Fertility and Sterility, 63, 742-746.
  • Nationa l Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039-1057.
  • Owen E. J., Shoham Z., Mason B. A., Ostergaar d H. and Jacobs H. S. (1991) Cotreatment with growth hormone after pituitary suppression for ovarian stimulation in in vitro fertilization: a randomized, double- blind, placebo -controlled trial. Fertility and Sterility, 56, 1104-1110.
  • Pekonen F., Laatikain en T., Buyalos R. and Rutanen E. (1989) Decrease d 34K insulin- like growth factor bindin g protein in polycystic ovary disease. Fertility and Sterility, 51, 972-975.
  • Polson D. W., Adams J., Wadsworth J. and Franks S. (1988) Polycystic ovaries -- a common finding in normal women. Lancet, 1, 870-872.
  • Poretsky L. and Piper B. (1994) Insulin resistanc e, hyperse cretion of LH, and dual-de fect hypothe sis for the patho genesis ovary syndro me. Obstetrics and Gynecolog y, 84, 613-621.
  • Prelevic G. M., Wurzburg er M. I., Balint- Peric L. and Nesic J. S. (1990) Inhibitory effect of sandostat in on secretio n of luteinizing hormone and ovarian steroid s in polycystic ovary syndro me. Lancet, 336, 900-903.
  • Prelevic G. M., Wurzburg er M. I. and Balint- Peric L. (1992a) The effect of somatostatin analog octreotide (sandostatin)onluteinizinghormoneandovaria n steroid s in insulin- dependent diabetic women without residual insulin secretion. Gynecolog ical Endocrino logy, 6, 259-263.
  • Prelevic G. M., Wurzburg er M. I., Balint-Peric L., Hardi-man P., Okolo S., Maletic D. and Ginsburg J. (1992b ) Effects of the somatostatin analogue, octreoti de, in polycystic ovary syndro me. M etabolism , 41, supplement 2, 76-79.
  • Prelevic G. M., Ginsbur g J., Maletic D., Hardiman P., Okolo S., Balint- Peric L., Thomas M. and Orskov H. (1995)Theeffectsofthesomatostatinanalogu e octreotide on ovulatory performance in women with polycystic ovaries. Human Reproduct ion, 10, 28-32.
  • Reichlin S. (1983) Somatostatin. (Part I and III). New England Journa l of Medicin e, 309, 1495-1503, 1556-1563.
  • Reis R. M., Foss M. C., de Moura M. D., Ferriani R. A. and Silva de SaÁ M. F. (1995) Insulin secretion in obese and non-ob ese women with polycystic ovary syndrome and its relations hip with hyperan drogenism. Gynecolog ical Endocrino logy, 9, 45-50.
  • Rosenbau m D., Haber R. S. and Dunaif A. (1993) Insulin resistanc einpolycysticovarysyndro medecrease d expressionofGLUT-4glucosetranspor tersin adipocy tes. American Journa l of Physiolog y, 264, 197-202.
  • Ruutiainen K. and Adashi E. Y. (1993) Intraov arian factors in hyperan drogeni sm. Seminars in Reproduct ive Endo-crinolog y, 11, 324-328.
  • Sharp P. S., Kiddy D. S., Reed M. J., Anyaoku V., Johnston D. G. and Franks S. (1991) Correlation of plasma insulin and insulin-like growth factor- 1 with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clinical Endocrinology, 35, 253-257.
  • Shoham Z., Jacobs H. S. and Insler V. (1993) Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersec reted during the follicular phase. Fertility and Sterility, 59, 1153-1161.
  • Suikkari A. M., Ruutiainen K., Erkkola R. and Seppala M. (1989) Low levels of low molecular weight insulin- liked growth factor-bindin g protein in patients with polycystic ovarian disease. Human Reproduct ion, 4, 136-139.
  • Sutterlin M. and Steck T. (1995) Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism. Gynecological Endocrino logy, 9, 37-44.
  • Taylor S. I., Dons R. F., Hernandez E., Roth J. and Gorden P. (1982) Insulin resistanc e associate d with androgen axcess in women with autoantibodies to the insulin receptor. Annals of Internal Medicine, 97, 851-855.
  • Velazquez E. M., Mendoza S., Hamer T., Sosa F. and Glueck C. J. (1994) Metformin therapy in polycystic ovary syndro me reduces hyperin sulinemia, insulin resistance, hyperan drogenemia, and systolic blood pressure , while facilitati ng normal menses and pregnan cy. M etab-olism , 43, 647-654.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.